The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality

Chien-Hsieh Chiang, MD, MPH, Chia-Wen Lu, MD, MSc, Hsieh-Cheng Han, PhD, Shou-Hung Hung, MD, Yi-Hsuan Lee, MD, Kuen-Cheh Yang, MD, MSc, and Kuo-Chin Huang, MD, PhD

Abstract: The relationship of diabetes and smoking status to hepatocellular carcinoma (HCC) mortality is not clear. We aimed to investigate the association of smoking cessation relative to diabetes status with subsequent deaths from HCC.

We followed up 51,164 participants (aged 44–94 years) without chronic hepatitis B or C from 1 January 1998 to 31 December 2008 enrolled from nationwide health screening units in a prospective cohort study. The primary outcomes were deaths from HCC.

During the study period, there were 253 deaths from HCC. History of diabetes was associated with deaths from HCC for both total participants (adjusted hazard ratio [HR], 2.97; 95% confidence interval [CI], 2.08–4.23) and ever smokers with current or past smoking habits (HR, 1.92; 95% CI, 1.10–3.34). Both never smokers (HR, 0.46; 95% CI, 0.32–0.65) and quitters (HR, 0.62; 95% CI, 0.39–0.97) had a lower adjusted risk of HCC deaths compared with current smokers. Among all ever smokers with current or past smoking habits, as compared with diabetic smokers, only quitters without diabetes had a lower adjusted risk of HCC deaths (HR, 0.37; 95% CI, 0.18–0.78). However, quitters with diabetes were observed to have a similar risk of deaths from HCC when compared with smokers with diabetes. Regarding the interaction between diabetes and smoking status on adjusted HCC-related deaths, with the exception of quitters without history of diabetes, all groups had significantly higher HRs than nondiabetic never smokers. There was also a significant multiplicative interaction between diabetes and smoking status on risk of dying from HCC (P = 0.033). We suggest clinicians should promote diabetes prevention and never smoking to associate with reduced subsequent HCC mortality even in adults without chronic viral hepatitis.

(Medicine 95(6):e2699)

INTRODUCTION

Hepatocellular carcinoma (HCC) ranks as a leading cause of cancer death, especially in Asia-Pacific regions. Risk factors for HCC include not only chronic viral hepatitis, alcoholic liver disease, and nonalcoholic fatty liver disease,1–3 but probably also metabolic risk factors such as diabetes mellitus (DM) with increasing concern.4–13 Smoking has been established to be related to higher hepatitis B viral load, HCC risks, and HCC mortality.14–17 However, much less research has investigated the relationship between smoking cessation and death from HCC,13 except for some hospital-based studies.19–21 There is also limited evidence studying the association between tobacco cessation and HCC-related death in individuals without chronic viral hepatitis.

Moreover, it usually takes much time of follow-up to study the effectiveness of smoking cessation. According to data from the Framingham Offspring Study collected from 1984 through 2011, the long-term benefit of smoking cessation for the significant reduction of cardiovascular diseases has only been shown in individuals not yet developing diabetes, rather than people with diabetes.22 The timing of smoking cessation seemed to impact a lot for the prevention of cardiovascular diseases. But there is still no evidence regarding whether quitters not yet having diabetes are at lower risk of dying of HCC. Therefore in this prospective community-based cohort without chronic hepatitis B or C, we aimed primarily to investigate the association between smoking cessation, diabetes and subsequent HCC-related death. Second, we explored whether smoking cessation when having no DM would associate with a reduced risk of dying from HCC in adults with smoking experience.

METHODS

Participants

All participants were recruited from several nationwide health screening units in Taiwan from 1 January 1998 to 31 December 2008. The detailed information of methods including sample size estimation and laboratory measurements has been described previously.11 We excluded participants with physician-diagnosed cancer of any types at study entry. We used a
Anthropometric Indices and Laboratory Measurements

At study entry, body height and weight were measured. Obesity was defined as a body mass index (BMI) ≥30 kg/m² recommended by the World Health Organization.25 Central obesity was defined as a waist circumference ≥80 cm for women or ≥90 cm for men. Blood pressure was measured through a standard mercury sphygmomanometer under standardized conditions. Each participant should fast for at least 12 hours prior to blood tests. Serum hepatitis B surface antigen, serum antibody to hepatitis C virus, plasma glucose, lipid, alanine aminotransferase (ALT), aspartate aminotransferase, and creatinine levels were measured as described previously.11 Subjects who had a fasting glucose level ≥100 mg/dL (5.56 mmol/L) or currently on medications for hyperglycemia were classified as having a high fasting plasma glucose. A plasma triglycerides level ≥150 mg/dL (1.70 mmol/L) denoted the hypertriglyceridemia, and a plasma total cholesterol level ≥200 mg/dL (5.18 mmol/L) denoted the hypercholesterolemia. A serum high-density lipoprotein cholesterol (HDL) level <40 mg/dL (1.04 mmol/L) in men and <50 mg/dL (1.29 mmol/L) in women defined the low HDL-C. We applied the 4-variable version of the Modification of Diet in Renal Disease Study equation for Chinese Patients to calculate estimated glomerular filtration rate (eGFR).25

Statistical Analysis

Values were presented as either a percent or mean (standard deviation) in descriptive analyses. In univariate analyses, we utilized the χ² test or Fisher exact test to compare categorical data and the 2-sample Student t test to compare continuous variables. Crude hazard ratios (HRs) and 95% confidence intervals (CIs) of selected risk factors for HCC-related deaths were estimated (PROC PHREG, SAS Institute, Cary, NC). We assumed missing values over time as missing at random and did listwise deletion. Participants lost to follow-up were assumed as mortality from competing risks. We conducted multivariate Cox regression analyses to estimate the adjusted HRs and 95% CIs of smoking habits and diabetes status for HCC-related deaths. A subgroup Cox regression analysis was performed among all ever smokers with current or past smoking habits. The interaction between diabetes history and smoking cessation was tested in this subgroup. The unadjusted Kaplan–Meier survival curves of deaths from HCC for subjects with different smoking habits were drawn. A lag time sensitivity analysis was performed by excluding the follow-up periods within the first quartile, median, and the third quartile of survival time among the subjects dying of HCC. All of the abovementioned analyses were performed with SAS 9.4. Statistical significance levels were determined by 2-tailed tests (P < 0.05).

RESULTS

Ever since 1 January 1998, we had invited 52,472 individuals from our health screening units. Excluded were 1308 participants who had preexisting cancer of any type (Figure 1). Finally a total of 51,164 eligible participants (aged 44–94 years) were included in the cohort, of whom 41,303 individuals without chronic hepatitis B or C completed the follow-ups. The total follow-up period lasted ten years (through 31 December 2008) with the median being 3316 days. There were 2657 deaths during follow-up with 253 deaths from HCC. At baseline, there were 22,325 female and 18,978 male participants. Individuals with diabetes tended to be older, male, had higher ALT levels, BMI, and waist circumference, but lower eGFR than those without diabetes (Table 1). Subjects with diabetes also had a higher prevalence of general and central obesity, hypertension history, hypertriglyceridemia, hypercholesterolemia, low HDL-C level, and adequate physical activity.

Metabolic Risk Factors for Hepatocellular Carcinoma-related Deaths

Using multivariate Cox regression analyses (Table 2), history of diabetes was associated with deaths from HCC for both total participants (HR, 2.97; 95% CI, 2.08–4.23) and ever smokers (n = 10,282) with current or past smoking habits (HR, 1.92; 95% CI, 1.10 to 3.34). Never smokers, quitters, and current smokers had significantly different probability of HCC mortality in the Kaplan–Meier survival curves (P < 0.0001) (Figure 2). Both never smokers (HR, 0.46; 95% CI, 0.32 to 0.65) and quitters (HR, 0.62; 95% CI, 0.39–0.97)
TABLE 1. Baseline Characteristics of Our Participants

| Factor                      | Nondiabetic (n = 38,563) | Diabetic (n = 2740) | P Value |
|-----------------------------|--------------------------|---------------------|---------|
| Age (y)                     | 56.4 (8.8)               | 61.0 (8.4)          | <0.001  |
| Sex                         |                          |                     | 0.006   |
| Female                      | 54.2                     | 51.5                |         |
| Male                        | 45.8                     | 48.5                |         |
| ALT (IU/L) *                | 27.1 (27.9)              | 31.5 (27.9)         | <0.001  |
| Body mass index (kg/m²)     | 24.1 (3.3)               | 24.9 (3.4)          | <0.001  |
| Obesity                     | 4.4                      | 6.6                 | <0.001  |
| Waist circumference (cm)†   | 80.7 (9.5)               | 84.9 (9.1)          | <0.001  |
| Central obesity †           | 32.6                     | 51.1                | <0.001  |
| Hypertension history        | 18.0                     | 42.3                | <0.001  |
| High triglycerides †        | 30.2                     | 53.1                | <0.001  |
| High cholesterol †          | 61.2                     | 64.0                | 0.004   |
| Low HDL-C ‡                 | 39.5                     | 52.3                | <0.001  |
| eGFR (ml/min/1.73 m²) ‡      | 81.4 (17.5)              | 79.9 (20.5)         | <0.001  |
| Smoking                      |                          |                     | <0.001  |
| Never                       | 73.7                     | 69.7                |         |
| Quitted                     | 7.5                      | 9.9                 |         |
| Current                     | 18.8                     | 20.5                |         |
| Alcohol consumption **      |                          |                     | <0.001  |
| Never                       | 75.9                     | 78.0                |         |
| Past                        | 5.0                      | 7.2                 |         |
| Habitual                    | 19.6                     | 14.8                |         |
| Adequate physical activity †| 40.5                     | 44.9                | <0.001  |

Data presented as mean (standard deviation) or percent.
ALT = alanine aminotransferase, HDL-C = high-density lipoprotein cholesterol, eGFR = estimated glomerular filtration rate calculated by the 4-variable version of the Modification of Diet in Renal Disease Study equation for Chinese Patients.
* Data missing for 66 participants.
† Data missing for 30 participants.
‡ Data missing for 5 participants.
§ Data missing for 1118 participants.
‖ Data missing for 9 participants.
¶ Data missing for 2591 participants.
‖‖ Data missing for 4664 participants.
‖‖‖ Data missing for 3338 participants.

had a lower adjusted risk of HCC deaths compared with current smokers (Table 2). Among all ever smokers with current or past smoking habits, as compared with diabetic smokers, only quitters without diabetes had a lower adjusted risk of HCC deaths from HCC (HR, 0.37; 95% CI, 0.18–0.78). However, quitters with diabetes were observed to have a similar risk of deaths from HCC when compared with smokers with diabetes. The lag time sensitivity analysis was performed respectively by excluding the follow-up periods within the first quartile (1233 days), median (2181 days), and the third quartile (2731 days) of survival time among our participants dying of HCC (Table 3). The reduced risk of HCC deaths in quitters without diabetes versus smokers with diabetes remained significant after leaving out all time lags of follow-up. Regarding the relationship between diabetes, smoking status, and adjusted HCC-related deaths (Table 4), with the exception of quitters without history of diabetes, all groups had significantly higher HRs than non-diabetic never smokers. There was also a significant multiplicative interaction between DM and smoking status on risk of dying from HCC (P = 0.033).

In subgroup analyses of quitters, neither previous smoking amount (P = 0.569), nor smoking-free period after quitting (P = 0.301) were significantly associated with risks of liver cancer-related death. A total of 17,116 participants in our cohort underwent ultrasonography and 9417 (55.0%) had hepatic steatosis. Participants with baseline hepatic steatosis had higher adjusted HCC mortality (HR, 2.73; 95% CI, 1.56–4.76). The significant association between diabetes and deaths from HCC persisted after controlling for hepatic steatosis. In the present

TABLE 2. Multivariate Analysis of Diabetes Status and Smoking Habits for Deaths From Hepatocellular Carcinoma in a Prospective Cohort

| Model                        | Total (Death = 253) | Ever Smokers (Death = 113) |
|------------------------------|---------------------|----------------------------|
| Diabetic versus nondiabetic  | 2.97 (2.08–4.23)    | 1.92 (1.10–3.34)           |
| Quitters versus current      | 0.62 (0.39–0.97)    | 0.69 (0.44–1.10)           |
| smokers                      |                     |                            |
| Never smokers versus         | 0.46 (0.32–0.65)    | –                          |
| current smokers              |                     |                            |
| Non-diabetic quitters versus | –                   | 0.37 (0.18–0.78)           |
| diabetic smokers             |                     |                            |
| Non-diabetic smokers         | –                   | 0.55 (0.28–1.07)           |
| versus diabetic smokers      |                     |                            |
| Diabetic quitters versus     | –                   | 0.81 (0.28–2.34)           |
| diabetic smokers             |                     |                            |
| Age (y)                      | 1.05 (1.04–1.07)    | 1.04 (1.02–1.07)           |
| Male versus female           | 1.16 (0.81–1.66)    | 1.63 (0.65–4.07)           |
| Obesity (yes versus no)      | 1.90 (1.11–3.26)    | 1.49 (0.54–4.12)           |
| Hypertension history (yes    | 1.12 (0.82–1.53)    | 1.45 (0.92–2.27)           |
| versus no)                   |                     |                            |
| High triglycerides (yes      | 0.40 (0.28–0.58)    | 0.44 (0.27–0.72)           |
| versus no)                   |                     |                            |
| High cholesterol (yes        | 0.43 (0.32–0.57)    | 0.50 (0.33–0.76)           |
| versus no)                   |                     |                            |
| Serum ALT level (IU/L)       | 1.01 (1.01–1.01)    | 1.01 (1.01–1.01)           |
| eGFR (ml/min/1.73 m²) ‡       | 0.99 (0.98 to 0.99) | 1.00 (0.99–1.01)           |
| Past alcohol consumption     | 1.83 (1.17–2.86)    | 1.82 (1.05–3.15)           |
| versus never                 |                     |                            |
| Habitual alcohol consumption | 1.22 (0.86–1.74)    | 1.20 (0.77–1.86)           |
| versus never                 |                     |                            |
| Physical activity (inadequate| 1.23 (0.93–1.64)    | 1.40 (0.91–2.14)           |
| versus adequate)             |                     |                            |

Data presented as HR (95% CI).
ALT = alanine aminotransferase; eGFR = estimated glomerular filtration rate calculated by the 4-variable version of the Modification of Diet in Renal Disease Study equation for Chinese Patients.
* P < 0.05.
† P < 0.01.
‡ P < 0.005.
§ P < 0.001.
cohort, a total of 2082 (76.0%) participants with diabetes received regular anti diabetic agents. Participants with diabetes and history of regular anti-diabetic agents had a similar risk of deaths from HCC (HR, 1.23; 95% CI, 0.56–2.70) compared with participants with diabetes but without regular antidiabetic agents, adjusted for age, sex, serum ALT level, eGFR, obesity, hypertension history, high triglycerides, and high cholesterol level. Data missing about smoking status for 2591 participants (17 HCC deaths).

**DISCUSSION**

Accumulating efforts have been made to reduce the burden of HCC, including early identification of potential risk factors other than the established ones like chronic viral hepatitis and excess alcohol consumption.2,12 A study analyzing patients with HCC referred to a specialist multidisciplinary team in England between 2000 and 2010 reported that nonalcoholic fatty liver disease increased dramatically and became the most common risk factor for HCC (34.8%) by 2010.26 Although chronic viral hepatitis remains a major risk factor of HCC in Taiwan,27,28 we have observed the association between certain viral factor, such as hepatitis B viral load and selected host metabolic factors.29–31 Furthermore, we demonstrated that diabetes was associated with increased HCC mortality even in the absence of chronic hepatitis B or C.11 Another prospective study in Taiwan also showed a higher risk of HCC mortality in those with type 2 DM, current smoking and use of insulin for over 10 years.17

**FIGURE 2.** Kaplan–Meier survival curves for never smokers, quitters, and current smokers. The log-rank test is significant with $P < 0.0001$ between never smokers and quitters, between never smokers and current smokers, and between total participants with different smoking habits. The Log-Rank test is not significant between quitters and current smokers with $P = 0.351$.

**TABLE 3.** Multivariate Lag-time Analysis of Diabetes Status and Smoking Habits for Deaths From Hepatocellular Carcinoma Among Ever Smokers

| Risk Factor         | Survival ≥ 1233 days n = 10,033 | Survival ≥ 2181 days n = 9748 | Survival ≥ 2731 days n = 9518 |
|---------------------|---------------------------------|--------------------------------|--------------------------------|
| Diabetic smokers    | Reference                        | Reference                      | Reference                      |
| Nondiabetic quitters| 0.33 (0.13–0.81)                 | 0.28 (0.09–0.82)                | 0.15 (0.03–0.69)               |
| Diabetic smokers    | 0.57 (0.26–1.25)                 | 0.50 (0.20–1.24)                | 0.37 (0.12–1.18)               |
| Diabetic quitters   | 0.96 (0.28–3.22)                 | 1.03 (0.25–4.19)                | 0.52 (0.06–4.82)               |

Data presented as HR (95% CI). The first quartile (1233 days), median (2181 days), and the third quartile (2731 days) of survival time among our ever smokers dying of HCC were chosen as the cut-off time lag. Adjusted by age, sex, serum alanine aminotransferase level, estimated glomerular filtration rate, alcohol consumption (habitual, past, never), adequate physical activity, obesity, hypertension history, high triglycerides, and high cholesterol level. Ever smokers: current smokers and quitters together. Nondiabetic quitters: quitters who reported having no history of diabetes. Diabetic quitters: quitters who reported having had diagnosis of diabetes.

**TABLE 4.** Relationship Between Diabetes and Smoking Status on Deaths From Hepatocellular Carcinoma in a Prospective Cohort

|  |  | HR (95% CI) |
|---|---|-------------|
|  | No | Never smoker 26,582 (98) 1.00 (Referent) |
|  | No | Quitters 2703 (23) 1.53 (0.91–2.59) |
|  | No | Current smokers 6774 (74) 2.49 (1.71–3.64) |
|  | Yes | Never smoker 1848 (25) 4.24 (2.68–6.70) |
|  | Yes | Quitters 262 (5) 3.28 (1.29–8.38) |
|  | Yes | Current smokers 543 (11) 4.73 (2.44–9.17) |

Data presented as HR (95% CI). Adjusted by age, sex, obesity, serum alanine aminotransferase level, estimated glomerular filtration rate, alcohol consumption (habitual, past, never), adequate physical activity, hypertension history, high triglycerides, and high cholesterol level. Data missing about smoking status for 2591 participants (17 HCC deaths). HR = Hazard ratio.

* $P < 0.05$.

$P < 0.0001$.
confounder like chronic viral hepatitis B. Neither did it directly evaluate the effect of smoking cessation. We moved on to study lifestyle factors, including the long-term benefit of smoking cessation without history of diabetes. Our results reveal that both never smokers and quitters had a lower risk of HCC deaths compared to current smokers. In addition, there was a significant multiplicative interaction between diabetes and smoking status. Only nondiabetic quitters had fewer deaths from HCC compared with diabetic smokers. Our findings are consistent with previous research regarding the positive association between DM and deaths from HCC.1,33 However, acknowledging diabetes as a risk factor contributes little to the reduction of HCC mortality in the real world. The worldwide surveillance for HCC is performed mainly for patients with chronic hepatitis or advanced hepatic fibrosis.1,33 Prescribing only antidiabetic agents with low risks of liver carcinogenesis is impractical and does not definitely lead to best outcomes for patients with diabetes.10,34 Therefore, preventing DM and declining smoking are more important, as we emphasize in the present report.

Smoking is one of major modifiable risk factor for incident DM.35,36 Smoking cessation improved insulin resistance, microalbuminuria, and the subsequent cardiometabolic complications.37–39 Smoking cessation also alleviated the hypoxia and oxidative stress-causing pancreatic beta-cell glucotoxicity.40 However, the benefit of smoking cessation in epidemiological studies is not so easily observed as that of never smoking. Although a 25-year prospective study reveals that early smoking cessation when having no diabetes was associated with significant reduction of cardiovascular diseases,41 the relatively short-term studies of smoking cessation yield some conflicting results. For example, a 9.2-year cohort of 2070 Japanese men without preexisting DM showed that risk for new-onset DM peaked within 3 years and persisted at 5 years after quitting smoking among overweight individuals.42 It was probably because investigators could not manipulate body weight after smoking cessation in this Japanese observational study. Although our 10-year cohort showed general protective effects of smoking cessation for fewer deaths from HCC (Table 2), only quitters without history of diabetes was associated with reduced HCC mortality. Once having diabetes, quitters did not independently have a lower risk of dying of HCC. The exact mechanism is unknown. A probable explanation is that diabetes was more crucial than smoking for an increased risk of dying from HCC (Table 4). Another reason is the time of smoking cessation of each quitter was not long enough to gain protection against HCC mortality.43 Besides, quitters having relapsed during study period would weaken the protection with bias toward the null.

A concern regarding the competing risks in observational studies deserves evaluation.44 Patients with diabetes and smoking habits might have earlier cardiovascular or acute lethal events, which may have impeded the occurrence of deaths from HCC. Accordingly, we performed a lag time sensitivity analysis by excluding follow-up periods within selected time lags to have fewer competing risks and less reverse causation. Non-diabetic quitters still had fewer deaths from HCC compared with diabetic smokers (Table 3). Among our participants with diabetes, there were 41 HCC-related deaths and 72 cardiovascular deaths. As for our ever smokers, there were 123 HCC-related deaths and 268 cardiovascular deaths. Even if a participant had been dead with concurrent HCC and cardiovascular disease, only 1 primary cause of death would be coded in Taiwan death certificates. Actually, the total HCC-related deaths (66.8 years, n = 253) in our cohort was younger than those with cardiovascular deaths (71.4 years, n = 535). Without autopsy, it is difficult to clarify the potential competing risks, especially if the diagnosis of HCC had never been made until death.45

This community-based study has to address some limitations. Our current cohort study was not fully representative of general population in Taiwan because we included only middle-aged or elderly individuals receiving health screening and excluded those infected with chronic viral hepatitis B or C. Liver fibrosis and cirrhosis is a major confounder of HCC incidence and mortality.33 However, it could not be quantified without transient elastography, magnetic resonance imaging, or liver biopsy in these health screening units. The screening units could not access every private biopsy result for HCC incidence. We excluded HCC patients at study entry and did not get available data to adjust the staging and treatment of HCC but some studies have reported that HCC patients with diabetes had higher mortality after adjusting the staging and treatment of HCC.75,22 In particular, Shau et al showed that the liver cancer-specific survival, liver disease-related survival, and overall survival rates were significantly worse for patients with DM than patients without DM (all P < 0.001). After adjusting for age, sex, tumor stage, and the presence of other comorbidities, DM remained an independent predictor of poorer liver cancer-specific survival (P < 0.001), liver disease-related survival (P < 0.001), and overall survival (P < 0.001).13 Thus the associations between DM and mortality were consistent among subgroups, irrespective of tumor size, stage, treatment modality, and liver cirrhosis.

Taiwan is an endemic area of hepatitis B virus. We could not get liver tissues of all participants to eliminate the presence of occult hepatitis B virus infection, though its direct contribution to HCC-related death has not yet been established.44 We could not assess the follow-up serostatus of chronic viral hepatitis, even though the likelihood of new infection was low under national policy.45 Several studies after 2005 reported that more cups of coffee consumption would reduce HCC incidence and mortality.34,46–49 A large Finnish study, including over 60,000 individuals across a 19-year follow-up period, showed a dose-dependent decrease of the rate of HCC-development in the consumption of up to 6 cups of coffee per day.48 However, we did not collect such dose-dependent information about coffee intake in our questionnaire launched from 1998.

Defining history of diabetes by patient-reported questionnaire could underestimate the prevalence of DM. The diagnostic accuracy would be improved if the fasting plasma glucose levels had been repeatedly checked based on the current diagnostic criteria.50 Residual confounding might come from the duration or the severity of DM, class of antidiabetic agents, and statins.34 Hepatocellular carcinoma occurrence has been reported to be positively associated with sulfonylureas and insulin,35,38,42,51,52 but these agents still play a mainstream role in diabetes care.50 The combination of high-risk insulin secretagogues with low-risk metformin and lipid-lowering agents is common in daily practice. In our cohort, participants with diabetes and treatment with antidiabetic agents had a similar risk of HCC mortality compared to participants with diabetes but without treatment with antidiabetic agents. Whether taking regular lipid-lowering agents or not among participants with hypertriglyceridemia had a similarly adjusted risk of deaths from HCC. In addition, we could not manipulate any change in body weight or metabolic factors after smoking cessation in this observational study. Future experimental research should investigate altogether the
effectiveness of smoking cessation and body weight control for long-term liver endpoints.

In conclusion, we prospectively demonstrated that both never smoking and smoking cessation were associated with reduced deaths from liver cancer independently of other possible confounders. Smokers should quit early when having no diabetes to associate with reduced future HCC-related deaths. Once having diabetes, quitters did not have a lower risk of dying of HCC even in adults without chronic hepatitis B or C. For daily practice especially in Asia-Pacific regions, we suggest clinicians prevent diabetes and arrange smoking cessation before patients get DM to reduce the subsequent HCC mortality.

ACKNOWLEDGMENTS

We thank Pei-Kun Sung, all staff of the health screening units, and all participants in this study.

REFERENCES

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.
2. Liao SF, Yang HI, Lee MH, et al. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One. 2012;7.e43779.
3. Wen CP, Lin J, Yang YC, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst. 2012;104:1599–1611.
4. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–121.
5. Inoue M, Kurahashi N, Iwasaki M, et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 2009;20:741–750.
6. Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43:1295–1302.
7. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54:533–539.
8. Brower V. Illuminating the diabetes-cancer link. J Natl Cancer Inst. 2012;104:1048–1050.
9. Chiang CH, Huang KC. Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:7213–7216.
10. Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28:109–122.
11. Chiang CH, Lee LT, Hung SH, et al. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology. 2014;59:2207–2215.
12. Chen J, Han Y, Xu C, et al. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Curr Prev. 2015;24:89–99.
13. Shau WY, Shao YY, Yeh YC, et al. Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist. 2012;17:856–862.
14. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:572–84.
15. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
16. Wang LY, You SL, Lu SN, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control. 2003;14:241–250.
17. Tseng CH. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int. 2013;7:693–702.
18. Ogimoto I, Shibata A, Kurozawa Y, et al. Risk of death due to hepatocellular carcinoma among smokers and ex-smokers. Univariate analysis of JACC study data. Kurume Med J. 2004;51:71–81.
19. Siegel AB, Conner K, Wang S, et al. Smoking and hepatocellular carcinoma mortality. Exp Ther Med. 2012;3:124–128.
20. Shih WL, Chang HC, Liaw YF, et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer. 2012;131:2612–2621.
21. Raffetti E, Portolani N, Molfini S, et al. Role of aetiology, diabetes, tobacco smoking and hypertension in hepatocellular carcinoma survival. Digest Liver Dis. 2015;47:950–956.
22. Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309:1014–1021.
23. Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol. 2000;29:336–343.
24. WHO., Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
25. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2927–2944.
26. Dyson J, Jaques B, Chattopadyay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–117.
27. Liu J, Yang HI, Lee MH, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology. 2014;60:77–86.
28. Chien YC, Jan CF, Chiang CJ, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014;60:125–132.
29. Chiang CH, Lai JS, Sheu JC, et al. The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. Obes Res Clin Pract. 2012;6:e31–e38.
30. Chiang CH, Yang HI, Jen CL, et al. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond). 2013;37:410–415.
31. Chiang CH, Lai JS, Hung SH, et al. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring). 2013;21:291–296.
32. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55:948–958.
33. Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744–751.
34. Singh S, Singh PP, Roberts LR, et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45–54.
35. Kowall B, Rathmann W, Strassburger K, et al. Association of passive and active smoking with incident type 2 diabetes mellitus in the elderly population: the KORA S4/F4 cohort study. Eur J Epidemiol. 2010;25:393–402.

36. Mozaffarian D, Marfisi R, Levantesi G, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet. 2007;370:667–675.

37. Bergman BC, Perreault L, Hunerdosse D, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes. 2012;61:3156–3166.

38. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.

39. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism. 2011;60:1456–1464.

40. Bensellam M, Laybutt DR, Jonas JC, et al. The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol. 2012;364:1–27.

41. Morimoto A, Ohno Y, Tatsumi Y, et al. Impact of smoking cessation on incidence of diabetes mellitus among overweight or normal-weight Japanese men. Diabetes Res Clin Pract. 2012;96:407–413.

42. Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58:783–787.

43. Chiang CH, Huang KC. Reply. Hepatology. 2015;61:1763–1764.

44. Chiang CH, Ni YH. Obscure clinical implication of occult hepatitis B virus infection by perinatal transmission despite prophylaxis with hepatitis B vaccination and HBIG Letter. J Hepatol. 2012;57:1401.

45. Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57:730–735.

46. Setiawan VW, Wilkens LR, Lu SC, et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015;148:118–125quiz e115.

47. Kurozawa Y, Ogimoto I, Shibata A, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer. 2005;93:607–610.

48. Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology. 2008;48:129–136.

49. Sang LX, Chang B, Li XH, et al. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol. 2013;13:34.

50. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64–71.

51. Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–891quiz 892.

52. Marchesini G, Forlani G. Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia. Hepatology. 2012;55:1298–1300.